Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's Disease: A retrospective cohort …
E Durukan, R Kraglund, SA Rashid… - International Journal of …, 2024 - nature.com
Abstract Treatment with Phosphodiesterase Type 5 inhibitors (PDE5is) has shown promise
in managing Peyronie's disease (PD) during its active phase. In a retrospective cohort study …
in managing Peyronie's disease (PD) during its active phase. In a retrospective cohort study …
Investigating the role of phosphodiesterases in myofibroblast transformation in Peyronie's disease
S Harding - 2024 - aru.figshare.com
Introduction: Peyronie's disease (PD) is characterised by a fibrous plaque that forms in the
penile tunica albuginea (TA), leading to pain, penile deformity, and erectile dysfunction …
penile tunica albuginea (TA), leading to pain, penile deformity, and erectile dysfunction …
Effect of Phosphodiesterase Type 5 Inhibitors in the Active Phase of Peyronie's Disease: A Retrospective Cohort Study
E Durukan, R Kraglund, S Rashid, T Thorkilgaard… - 2023 - researchsquare.com
Objectives Experimental models and preliminary human trials have implied that continuous
treatment with Phosphodiesterase Type 5 inhibitors (PDE5is) may be a viable treatment of …
treatment with Phosphodiesterase Type 5 inhibitors (PDE5is) may be a viable treatment of …